HC Wainwright Has Bearish Outlook for Zura Bio Q1 Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Zura Bio in a research note issued to investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.21) for the quarter, down from their prior forecast of ($0.20). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio's Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.85) EPS.

Other analysts have also issued research reports about the company. Oppenheimer restated an "outperform" rating and set a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital decreased their price objective on Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Finally, Guggenheim reaffirmed a "buy" rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $14.67.

Zura Bio Stock Up 8.0 %

Shares of NASDAQ ZURA traded up $0.09 during midday trading on Monday, reaching $1.21. 181,510 shares of the company's stock traded hands, compared to its average volume of 390,547. The company has a market cap of $82.73 million, a price-to-earnings ratio of -2.28 and a beta of 0.08. The stock's 50 day simple moving average is $1.32 and its 200-day simple moving average is $2.50. Zura Bio has a one year low of $0.97 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter.

Institutional Trading of Zura Bio

A number of institutional investors have recently made changes to their positions in the business. American Century Companies Inc. acquired a new position in Zura Bio during the 4th quarter valued at about $27,000. Prudential Financial Inc. purchased a new stake in shares of Zura Bio during the fourth quarter worth about $28,000. Two Sigma Advisers LP acquired a new position in shares of Zura Bio during the fourth quarter valued at about $32,000. ProShare Advisors LLC purchased a new position in shares of Zura Bio in the 4th quarter valued at approximately $35,000. Finally, XTX Topco Ltd purchased a new position in shares of Zura Bio in the 4th quarter valued at approximately $44,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.